RE-021 (Sparsentan)

Drug identity checked against registry records

Also recorded as Sparsentan

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisNCT01613118TVTXPhase 2Completed2016-06Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.